

How Are We Personalizing
Integration of ICIs and
Targeted Therapies to
Optimize **OUTCOMES IN
ENDOMETRIAL CANCER?**

IN-PERSON + VIRTUAL SATELLITE SYMPOSIUM

FRIDAY, JUNE 3, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Bradley J. Monk, MD, FACS, FACOG

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: How Are We Personalizing Integration of ICLs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?**

This program will deliver differing and provocative opinions and management approaches from experts who are well versed in the treatment of endometrial cancer (EC). The program will provide you with updates related to the current knowledge of the underlying biology of EC and the importance of biomarker testing. In addition, up-to-date information regarding the efficacy and safety of immunotherapies and targeted agents for EC, and evidence-based approaches to the management of treatment-related adverse events will be addressed. Detailed case presentations and panel discussions on controversial issues will provide clinicians with an intimate look into how experts approach individualized management of patients with this EC.

In working with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with endometrial cancer.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will create a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Bradley J. Monk, MD, FACS, FACOG

Professor

Division of Gynecologic Oncology

University of Arizona College of Medicine

Creighton University School of Medicine

Phoenix, AZ

Phil Talamo, CHCP

President

Physicians' Education Resource®, LLC

Cranbury, NJ

ptalamo@gotoper.com

AGENDA

7:00 PM	Welcome, Introductions, and Pre-session Survey	Bradley J. Monk, MD, FACOG, FACS
7:10 PM	Endometrial Cancer Immunobiology and Rationale for Biomarker Testing, IO and non-IO Biomarkers	Matthew Powell, MD
7:40 PM	Clinical Updates on Therapeutic Data: ICI Data, Targeted Therapies, Combinations, and New Directions in Endometrial Cancer	Moderator: Bradley J. Monk, MD, FACOG, FACS Panelists: Lucy Gilbert, MD MSc FRCOG; Bhavana Pothuri, MD; Matthew Powell, MD
8:25 PM	Identifying and Managing Treatment-Related Toxicities in Patients with Endometrial Cancer	Lucy Gilbert, MD MSc FRCOG; Bhavana Pothuri, MD
8:45 PM	Post-session Survey	Bradley J. Monk, MD, FACOG, FACS
8:55 PM	Closing remarks	Bradley J. Monk, MD, FACOG, FACS
9:00 PM	Adjourn	

Upcoming PER® Conferences			2022
●	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
●	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
●	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
●	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
●	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
●	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
●	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
●	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
●	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
●	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10

 Virtual Conference
  In-Person + Virtual Conference

Target Audience

This educational program is directed toward medical and gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists involved in the treatment and management of EC. Obstetrician/gynecologists, nurses, physician assistants, fellows, residents, and other health care professionals with an interest in EC also are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Evaluate the rationale for using genetic testing strategies in managing EC through biomarker-based decision-making
- Summarize key results of clinical trials involving emerging treatments and combinations of therapy in patients with EC, as guided by biomarkers and genomic data
- Describe relevant supportive measures in timely detection and management of potential treatment-related adverse events with therapies for EC
- Explain the most efficient uses of biomarker-based therapy along with other relevant evaluation strategies to formulate personalized treatment plans

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER[®] website by 12:00 PM EDT Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/endo0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/endo0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 3, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource[®], LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from GlaxoSmithKline and Karyopharm Therapeutics.

Thank you for attending **Medical Crossfire[®]: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau
Lucy Gilbert, MD, MSc, FRCOG	Institutional Grants: Alkermes, AstraZeneca, Esperas Pharma, Karyopharm, K-Group Beta Inc., IMV, ImmunoGen Inc., Merck Sharp & Dohme, Mersana, Novocure GmbH, Oncoquest, Pfizer, Roche, Tesaro	Alkermes, AstraZeneca, Eisai, Eisai-Merck, GlaxoSmithKline, Merck	
Bradley J. Monk, MD, FACS, FACOG		Agenus, Akeso, Aravive, AstraZeneca, Clovis, Eisai, Elevar Therapeutics, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Iovance, Karyopharm, Merck, Mersana, McKesson, Myriad, Novacure, Pfizer, Puma Biotechnology, Tesaro/GlaxoSmithKline Roche/Genentech, VBL Therapeutics, Sorrento Therapeutics	AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro
Bhavana Pothuri, MD, MS	Clovis Oncology, GlaxoSmithKline, Roche/Genentech, Merck, Eisai, Karyopharm	Advisory Boards: Clovis Oncology, Tesaro, Merck, Eisai, Sutro	
Matthew A. Powell, MD		Eisai Co., Ltd., GlaxoSmithKline/Tesaro, Merck, Clovis Oncology, Seagen	

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer


This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Experience
the new
gotoper.com



Streamlining
education
for the busy
clinician



Program Chair

**Bradley J. Monk, MD, FACS, FACOG**

Professor

Division of Gynecologic Oncology

University of Arizona College of Medicine

Creighton University School of Medicine

Phoenix, AZ

Bradley J. Monk, MD, FACS, FACOG, graduated at the top of his class from the University of Arizona College of Medicine-Tucson in 1988 and went on to complete a residency in obstetrics and gynecology at the University of California, Los Angeles. Between 1988 and 1995, he was the recipient of 3 fellowships in medical genetics and gynecologic oncology. In 2016, he became a member of Arizona Oncology and part of The US Oncology Network and continues to practice in Phoenix. Most recently, he was named medical director of gynecologic oncology for The US Oncology Network. He also is a professor on the clinical scholar track at the University of Arizona College of Medicine-Phoenix and works at Arizona Oncology (The US Oncology Network). He was named one of Arizona's Top Doctors by *Phoenix* magazine for 5 consecutive years beginning in 2012.

Monk's research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology and biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He was the first to report the activity of antivascular growth factor (VEGF) therapy in ovarian cancer and his papers in *The New England Journal of Medicine* led to the global approval of anti-VEGF therapy in recurrent ovarian and cervical cancers in 2014. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Monk was awarded the Ernest Wertheim Award for his research in cervical cancer and is on the board of directors for the GOG Foundation and is chair of the cervical cancer subcommittee for NRG Oncology. He also chairs the cervical cancer committee for the Gynecologic Cancer InterGroup. He has authored more than 275 peer-reviewed articles along with 31 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.

Faculty

**Lucy Gilbert, MD, MSc, FRCOG**

Professor

Department of Obstetrics & Gynecology

Department of Oncology

McGill University

Director, Gynecologic Cancer Service

McGill University Health Centre - Glen Site

Cedars Cancer Centre

Montreal, QC, Canada

Lucy Gilbert, MD, MSc, FRCOG, is a professor in the department of obstetrics and gynecology and the department of oncology at McGill University (MU) in Montreal, Quebec, Canada. She also is the director of gynecologic oncology at MU and McGill University Health Centre (MUHC), which is a designated level-IV unit that provides gynecological cancer care for the province of Quebec. Gilbert heads the Women's Health Research Unit of the MUHC, which focuses on research that produces practical and immediate benefits for women with cancer. The Women's Health Research Unit is active in collaborative multinational clinical trials investigating new precision therapies for gynecologic cancers.

Gilbert's main area of interest is the early detection of ovarian and uterine cancers while they are still curable. To this end, she has set up a network of satellite clinics called DOvEE (Diagnosing Ovarian and Endometrial Cancers Early), which provide open access and fast-track investigations to women over age 45 with symptoms associated with gynecologic cancers. She and her team have developed a new genetic PAP test called DOvEEgene for detecting these cancers very early before they even cause symptoms. Her team has completed the phase 1 and 2 testing of the DOvEEgene test and the team is set to launch phase 3.


Bhavana Pothuri, MD, MS

Professor

Department of Obstetrics and Gynecology

Division of Gynecologic Oncology

Grossman School of Medicine

New York University

Gynecologic Oncologist

NYU Langone Health

New York, NY

Bhavana Pothuri, MD, MS, is a board-certified gynecologic oncologist with more than 15 years of experience diagnosing, treating, and caring for women with gynecologic cancer.

As a professor in the department of obstetrics and gynecology at New York University's Grossman School of Medicine in New York, New York, she is actively involved in training medical students, residents, and fellows. Pothuri also is the director of gynecologic oncology clinical trials. Her research is currently focused on clinical trials involving new treatments for ovarian and endometrial cancer. She earned her medical degree from Jefferson Medical College at Thomas Jefferson University in Philadelphia, Pennsylvania, and a master's degree in biostatistics from Columbia University in New York, New York. She completed a fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center in New York, New York.

Pothuri is an expert surgeon skilled in minimally invasive laparoscopic and robotic assisted surgery and extensive radical debulking procedures, where malignant tumors are removed to make additional therapies more effective. Those additional therapies include chemotherapy and radiation.

Pothuri has been the recipient of several awards and recognized for teaching and research. She is a member of several professional societies, including the Society of Gynecologic Oncology, NRG Oncology, and the American Society of Clinical Oncology.


Matthew A. Powell, MD

Professor

Chief

Division of Gynecologic Oncology

Washington University School of Medicine

Chair, Uterine Corpus Cancer Subcommittee

NRG Oncology

St Louis, MO

Matthew A. Powell, MD, is a professor of obstetrics and gynecology and chief of the division of gynecologic oncology at Washington University School of Medicine in St. Louis, Missouri. He also serves as chair of the uterine corpus cancer subcommittee for NRG Oncology. Powell earned his medical degree from Michigan State University in East Lansing, Michigan. He completed a residency in obstetrics and gynecology at The Ohio State University Hospital in Columbus, Ohio, and a fellowship in gynecologic oncology at Washington University.

Powell's clinical research interests are primarily in the diagnosis and treatment of uterine and ovarian cancers with chemotherapy and radiation. He also is studying pharmacologic treatment of preinvasive abnormalities of the uterine cervix to help some patients avoid surgery and loss of fertility. His laboratory research focuses on endometrial cancer etiology and tumor marker development.

ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

**40th Annual
CFS**®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY

In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.



100 EXPERT
FACULTY
MEMBERS



25 TUMOR
TYPES



3 DAYS



1 MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com